SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Insys Therapeutics Inc. (INSY)

INSY RSS Feed
Add INSY Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 9/24/2016 10:54:11 AM - Followers: 56 - Board type: Free - Posts Today: 0


 

PLEASE READ THE DRUG MASTER FILE DMF# 28255 LOCATED HERE- http://www.insysrx.com/wp-content/uploads/2014/06/INSYS062014.pdf

Better Patient Care Through Innovation

We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products.

We have two marketed products, SUBSYS and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. Our lead pipeline product candidate is Dronabinol Oral Solution, a proprietary orally-administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market Dronabinol Oral Solution and any other future supportive care products, if approved, through our commercial organization.

Featured Product

devicephoto

Fentanyl SL Spray

INSYS has developed a fentanyl sublingual spray for the treatment of BTCP in opioid-tolerant patients.

 

 

 
Fentanyl SL - a proprietary, single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue.
Dronabinol product family - a portfolio of dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS.
-
View More >

Recent News

Relationships

partnering-featured

INSYS Therapeutics seeks to build long-term relationships with a focus on strategic alliances and deals that strengthen our business.

Learn More >

Innovative Pharmaceutical Products

We are assembling a product pipeline targeting cancer-supportive care and cancer therapy that we believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization.

Drug Indication Preclinical-  Phase 1-    Phase 2/3-   NDA-   Approved-        
Fentanyl Sublingual Spray BTCP in Opioid Tolerant Patients
       
Dronabinol SG (Generic Marinol®) 2nd Line CINV
       
Dronabinol Oral Solution (Pre-NDA) 2nd Line CINV
       

Generic Marinol Products (link)
In August 2011, the FDA Office of Generic Drugs approved our ANDA application for our  Dronabinol SG Capsule, and this product was launched through a distribution partner. In addition, INSYS is developing a novel dronabinol generic.

 

Our supportive care products include a proprietary sublingual fentanyl spray for the treatment of breakthrough cancer pain (BTCP), and our family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting (CINV), and appetite stimulation in AIDS patients.  We are also developing proprietary cancer therapeutics, the most advanced of which is LEP-ETU, an improved formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane.

***********************************************************************************************************************************************************************************************************************************************************************************


Commercial-stage specialty pharmaceutical company focused on innovative supportive care productsSubsys®: Proprietary sublingual fentanyl spray for breakthrough pain in cancer patients Launched in March 2012 through Insys sales force
Over 37% market share

PLEASE READ THE DRUG MASTER FILE DMF# 28255 LOCATED HERE- http://www.insysrx.com/wp-content/uploads/2014/06/INSYS062014.pdf 



Executive Team
 

Michael L. Babich

President and Chief Executive Officer

 
Michael L. Babich has served as our President since November 2010 and was appointed as our Chief Executive Officer in March 2011. From March 2007 until November 2010, Mr. Babich served as the Chief Operating Officer and a director of INSYS Pharma, Inc., a wholly-owned subsidiary of our company which is responsible for the initial development of Dronabinol SG Capsule and many of our product candidates, including Subsys and our other dronabinol product candidates. Prior to that, from 2001 to 2007 Mr. Babich worked at EJ Financial Enterprises, Inc., a venture capital firm specializing in early stage and startup investments primarily in the healthcare sector.

During his time at EJ Financial Enterprises, Mr. Babich held various roles and worked on various projects, including private equity transactions, asset management and strategic consulting for both public and private companies. Prior to his work at EJ Financial Enterprises, Mr. Babich worked at the Northern Trust Corporation managing mid- to large-cap portfolios for high net worth individuals. Mr. Babich also has served as a director and in management roles at Alliant Pharmaceuticals, Inc.

Mr. Babich received a B.A. from the University of Illinois at Urbana-Champaign and an MBA from the Kellogg School of Management at Northwestern University.

Darryl S. Baker

Chief Financial Officer

 
Darryl S. Baker has served as our Chief Financial Officer since October 2012. From 1997 to 2012, Mr. Baker served as Chief Financial Officer and Corporate Controller for various publicly-traded and entrepreneurial companies, including iGo, a developer of power management solutions and accessories for mobile electronic devices, Integrated Information Systems, a provider of secure integrated information technology solutions, and SkyMall, an integrated specialty retailer. Prior to 1997, Mr. Baker was an audit manager for Ernst & Young LLP.

Mr. Baker has extensive experience in accounting, SEC issues for smaller public companies, merger and acquisition transactions, and small business financing and frequently serves as a panelist and lecturer for the Center for Professional Education on various topics including SEC compliance, share-based compensation, revenue recognition, fair value and lease accounting. Mr. Baker earned his BS in Accountancy from the Marriott School of Management at Brigham Young University and is a Certified Public Accountant in the states of California and Arizona and is also a Chartered Global Management Accountant.
 

Christopher F. Homrich

Senior Vice President, Operations

 
Christopher F. Homrich has served as our Senior Vice President of Operations since February 2014. Mr. Homrich has served in executive and leadership positions in both public and private company settings including NCR Corporation, a technology company delivering assisted and self-service solutions and support to retail, financial, travel, hospitality, and public sector organizations, Ingram Industries, Inc., with diversified businesses in marine transportation, aggregate supply, book distribution, print on demand book manufacturing, and digital storage, management and distribution services, and Stryker Corporation, one of the world’s leading medical technology companies offering a diverse array of innovative medical technologies, including reconstructive, medical, surgical, and neurotechnology and spine products and devices.

Mr. Homrich earned his B.A. in Finance from Michigan State University and an MBA from the Eli Broad College of Business at Michigan State University.

Franc Del Fosse

General Counsel

 
Franc Del Fosse has served as our General Counsel since February 2014. Mr. Del Fosse joins our company from private practice, where he regularly advised public company boards, management and in-house counsel on the critical issues affecting their businesses. In addition, as a transactional attorney, he specialized in corporate and project financing, compliance with federal securities laws and mergers and acquisitions advisement.

Immediately prior to joining our company, Mr. Del Fosse was a partner at the law firm of Snell & Wilmer LLP. From 2001-2005, Mr. Del Fosse was an associate at the law firm of Shearman & Sterling. Mr. Del Fosse holds a J.D. degree from Columbia University School of Law and an undergraduate degree from Arizona State University. He is a member of the State Bar of California and Arizona.

 

Board of Directors

Michael L. Babich

President and Chief Executive Officer

 
Michael L. Babich has served as our President since November 2010 and was appointed as our Chief Executive Officer in March 2011. From March 2007 until November 2010, Mr. Babich served as the Chief Operating Officer and a director of INSYS Pharma, Inc., a wholly-owned subsidiary of our company which is responsible for the initial development of Dronabinol SG Capsule and many of our product candidates, including Subsys and our other dronabinol product candidates. Prior to that, from 2001 to 2007 Mr. Babich worked at EJ Financial Enterprises, Inc., a venture capital firm specializing in early stage and startup investments primarily in the healthcare sector.

During his time at EJ Financial Enterprises, Mr. Babich held various roles and worked on various projects, including private equity transactions, asset management and strategic consulting for both public and private companies. Prior to his work at EJ Financial Enterprises, Mr. Babich worked at the Northern Trust Corporation managing mid- to large-cap portfolios for high net worth individuals. Mr. Babich also has served as a director and in management roles at Alliant Pharmaceuticals, Inc.

Mr. Babich received a B.A. from the University of Illinois at Urbana-Champaign and an MBA from the Kellogg School of Management at Northwestern University.

John N. Kapoor, Ph.D.

Executive Chairman

 
John N. Kapoor, Ph.D. has served on our board of directors since our formation in 1990 and has served as Chairman from 1990 to 2004 and Executive Chairman since June 2006. Dr. Kapoor also served as a director of Insys Pharma from its inception in 2002. Dr. Kapoor has served as the President and Chairman of the board of directors of EJ Financial Enterprises since forming the company in 1990. Dr. Kapoor is also the Managing Partner of Kapoor-Pharma Investments, an investment company that he founded in 2000. Dr. Kapoor serves as the chairman of the board of directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, where he served as the Chief Executive Officer from March 2001 to December 2002 and from May 1996 to November 1998. Dr. Kapoor also served as the chairman of the board of directors of Sciele Pharma and OptionCare, Inc., a specialty pharmaceutical services company, where he served as Chief Executive Officer from August 1993 to April 1996.

Dr. Kapoor received his Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and a B.S. in Pharmacy from Bombay University in India.

Patrick P. Fourteau

 

 
Patrick P. Fourteau has served on our board of directors since March 2011. Mr. Fourteau served as President and Chief Executive Officer of Shionogi from 2008 until 2010. Prior to the acquisition of Sciele by Shionogi and Co. Ltd., Mr. Fourteau served as President and CEO of Sciele Pharma from 2003 until 2008 and served on the board of directors of Sciele from 2004 until 2008. He is a seasoned pharmaceutical industry executive having over 30 years of healthcare industry experience, with particular expertise in executing sales strategies for pharmaceutical products. Mr. Fourteau served as President of Worldwide Sales of inVentiv Health, Inc. from 2000 to 2002. Mr. Fourteau served as President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company prior to 1995.

Mr. Fourteau earned his B.A. and M.A. in Mathematics from the University of California, Berkeley and an MBA from Harvard University.

Pierre Lapalme

 

 
Pierre Lapalme has served on our board of directors since March 2011. Mr. Lapalme has also served as a member of the Board of Directors of BioMarin Pharmaceutical Inc., a biopharmaceutical company, since January 2004. From 1995 until his retirement in 2003, he served as the President and Chief Executive Officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry, including Chief Executive Officer and Chairman of the Board of Rhône-Poulenc Pharmaceuticals, Inc., from 1979 to 1994, and Senior Vice President and General Manager of North America Ethicals, divisions of Rhône-Poulenc Rorer, Inc. (which in 1999 merged with Hoechst AG to form Aventis, which then went on to merge with Sanofi-Synthélabo forming Sanofi-Aventis). Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada where he played a role in reinstituting certain patent protection for pharmaceuticals.

Mr. Lapalme studied at the University of Western Ontario and INSEAD France.

Steven Meyer

 

 
Steven Meyer has served on our board of directors since November 2010. From August 2007 until November 2010, Mr. Meyer served as a director of Insys Pharma. Since November 2005, Mr. Meyer has served as the Chief Financial Officer of JVM Realty Corporation, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company, where he served as Corporate Treasurer from January 1997 to July 2004.

Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Campaign-Urbana. He is an Illinois Certified Public Accountant.

Brian Tambi

 

 
Brian Tambi has served on our board of directors since November 2010. Mr. Tambi currently serves as a member of the board of directors of Akorn, Inc., a publicly traded pharmaceuticals company. From August 2007 until the November 2010, Mr. Tambi served as a director of Insys Pharma.

Since forming the company in January 2007, Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of BrianT Laboratories LLC, a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. Prior to that, since 1995 Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. and he currently serves as Morton Grove’s non-executive Chairman of the Board. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva Pharmaceutical Industries Ltd.), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb.

Mr. Tambi earned his MBA in International Finance & Economics in 1974 and his B.S. in Corporate Finance in 1972, both from Syracuse University.

Theodore H. Stanley, M.D.

 

 
Theodore H. Stanley, M.D., has served on our board of directors since March 2013. Since July 2009, Dr. Stanley has served as a managing director of UpStart Ventures, a venture capital fund focusing on investments in life sciences companies, and since 1978, Dr. Stanley has been a full time professor in the Department of Anesthesiology at the University of Utah, School of Medicine. In 1985, Dr. Stanley co-founded Anesta Corp., a publicly held pharmaceutical company focusing on the development of transmucosal drug products, including its lead product, Actiq, which was co-invented by Dr. Stanley in 1983. From 1985 to December 1997, Dr. Stanley served as chairman of the board of Anesta and served as Anesta’s Medical Director until April 1994, following which he served as founding chairman from January 1998 until the sale of Anesta to Cephalon in October 2000. In 1996, Dr Stanley co-founded ZARS Pharma, Inc., a privately held specialty pharmaceutical company that focused on the development and commercialization of topically administered drugs primarily in the area of pain management. Dr. Stanley served as chairman of the board of directors of ZARS Pharma until its acquisition in May 2011 by Nuvo Research Inc., a publicly held Canadian pharmaceutical company, of which Dr. Stanley currently serves as a director. Dr. Stanley also serves on the board of directors of seven privately held life sciences companies, four of which he serves as chairman of the board. Dr. Stanley earned his M.D. degree from Columbia University, College of Physicians and Surgeons (Medical Science), as well as an A.B. from Columbia College

Corporate Offices

INSYS Therapeutics, Inc.

1333 South Spectrum Blvd, Suite 100

Chandler, AZ 85286

Phone: (602) 910-2617

Fax: (602) 910-2627


$INSY recent news/filings

Filings here- https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001516479&owner=include&count=40&hidefilings=0
                        http://www.otcmarkets.com/stock/insy/filings
News here- http://www.prnewswire.com/search-results/news/insys-180-days-page-1
                      http://finance.yahoo.com/q/h?s=INSY+Headlines

News-

Tuesday, August 26, 2014

Insys Therapeutics' Cannabidiol Gets Orphan Drug StatusZacks (Tue, Aug 26)

Monday, August 25, 2014

FDA names potential Insys treatment an orphan drugAP (Mon, Aug 25)

Friday, August 22, 2014

INSYS THERAPEUTICS, INC. FinancialsEDGAR Online Financials (Fri, Aug 22)
Novus Aims to Make Medical Cannabis AffordableAccesswire (Fri, Aug 22)

Monday, August 18, 2014

INSYS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to RigEDGAR Online (Mon, Aug 18)

Thursday, August 14, 2014

INSYS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online (Thu, Aug 14)

Tuesday, August 12, 2014

http://news.investors.com/081214-712833-stocks-stake-out-thin-gains-early-tuesday.htm?ven="yahoocp&src=aurlled&ven=yahoo"" rel="nofollow" target="_blank">http://news.investors.com/081214-712833-stocks-stake-out-thin-gains-early-tuesday.htm?ven=yahoocp&src=aurlled&ven=yahoo"; rel="nofollow">Stocks Stake Out Thin Gains; Intercept, Insys, Autohome Gainat Investor's Business Daily (Tue, Aug 12)
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online (Tue, Aug 12)
http://news.investors.com/081214-712824-stock-futures-indecisive-tuesday.htm?ven="yahoocp&src=aurlled&ven=yahoo"" rel="nofollow" target="_blank">http://news.investors.com/081214-712824-stock-futures-indecisive-tuesday.htm?ven=yahoocp&src=aurlled&ven=yahoo"; rel="nofollow">Stock Futures Hem And Haw; Intercept Pharmaceuticals Soarsat Investor's Business Daily (Tue, Aug 12)
Q2 2014 Insys Therapeutics Inc Earnings Release - Before Market OpenCCBN (Tue, Aug 12)

Monday, August 11, 2014

Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech InvestmentAccesswire (Mon, Aug 11)

Friday, August 8, 2014

http://news.investors.com/080814-712488-gwph-insy-race-with-competing-epilepsy-drugs.htm?ven="yahoocp&src=aurlled&ven=yahoo"" rel="nofollow" target="_blank">http://news.investors.com/080814-712488-gwph-insy-race-with-competing-epilepsy-drugs.htm?ven=yahoocp&src=aurlled&ven=yahoo"; rel="nofollow">GW Pharma, Insys Face Off In Cannabis Drug Spaceat Investor's Business Daily (Fri, Aug 8)

Friday, July 11, 2014

MONDAY DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against INSYS Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of July 14, 2014 -- INSYPR Newswire (Fri, Jul 11)
"" rel="nofollow" target="_blank">http://www.fool.com/investing/general/2014/07/11/is-this-marijuana-stock-gw-pharmaceuticals-biggest.aspx?source=eogyholnk0000001"; rel="nofollow">Is This Marijuana Stock GW Pharmaceuticals' Biggest Risk?at Motley Fool (Fri, Jul 11)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against INSYS Therapeutics, Inc. and Certain Officers - INSYMarketwired (Fri, Jul 11)

Thursday, July 10, 2014

INSYS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against INSYS Therapeutics, Inc. - INSYMarketwired (Thu, Jul 10)
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against INSYS Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of July 14, 2014Business Wire (Thu, Jul 10)

Wednesday, July 9, 2014

Insys Completes Study on Dronabinol Oral SolutionZacks (Wed, Jul 9)
Faruqi & Faruqi, LLP Reminds Investors in INSYS Therapeutics, Inc. (INSY) of Imminent Deadline to Protect Your RightsGlobeNewswire (Wed, Jul 9)

Tuesday, July 8, 2014

INSYS Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and DirectorsBusiness Wire (Tue, Jul 8)

 

$INSY charts





 

$INSY company information

Link: http://www.otcmarkets.com/stock/INSY/company-info
Ticker: $INSY
OTC Market Place: NASDAQ LISTED
CIK code: 0001516479
Company name: Insys Therapeutics Inc.
Company website: http://www.insysrx.com
Incorporated In: DE, USA

 

$INSY share structure

Market Value: $1,100,341,042 a/o Aug 29, 2014
Shares Outstanding: 32,230,259 a/o Mar 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0002145


 
$INSY extra dd links


Company name: Insys Therapeutics Inc.
Company website: http://www.insysrx.com

STOCK DETAILS
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/INSY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/INSY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=INSY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=INSY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=INSY+Industry

COMPANY NEWS
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/INSY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/INSY/news - http://finance.yahoo.com/q/h?s=INSY+Headlines

STOCK ANALYSIS
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/INSY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/INSY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/INSY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/INSY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/INSY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/INSY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/INSY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/INSY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=INSY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/INSY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Insys+Therapeutics+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Insys+Therapeutics+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Insys+Therapeutics+Inc.&x=0&y=0
WHOIS (domaintools.com): "" rel="nofollow" target="_blank">; rel="nofollow">http://whois.domaintools.com/http://www.insysrx.com
Alexa (alexa.com): "" rel="nofollow" target="_blank">; rel="nofollow">http://www.alexa.com/siteinfo/http://www.insysrx.com#
Corporate website internet archive (archive.org): "" rel="nofollow" target="_blank">; rel="nofollow">http://web.archive.org/web/*/http://www.insysrx.com

FUNDAMENTALS
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/INSY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/INSY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/INSY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/INSY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/INSY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001516479&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/INSY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/INSY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/INSY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/INSY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=INSY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=INSY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/INSY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=INSY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=INSY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=INSY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=INSY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=INSY+Cash+Flow&annual

HOLDINGS
Major holdings (cnbc.com): http://data.cnbc.com/quotes/INSY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=INSY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/INSY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=INSY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/INSY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/INSY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/INSY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/INSY/insider-transactions

SOCIAL MEDIA AND OTHER VARIOUS SOURCES
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/INSY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/INSY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/INSY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=INSY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INSY

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INSY
Current Price
Volume:
Bid Ask Day's Range
SureTrader
INSY News: Current Report Filing (8-k) 09/21/2016 11:01:29 AM
INSY News: Insys Therapeutics Announces CEO Succession Plan 09/21/2016 07:00:00 AM
INSY News: Statement of Changes in Beneficial Ownership (4) 09/01/2016 04:24:45 PM
INSY News: Insys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference 09/01/2016 07:00:00 AM
INSY News: Purcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board... 08/30/2016 08:07:00 AM
PostSubject
#950   I still own it as one of the kevindenver 09/24/16 10:54:11 AM
#949   Good article..http://www.thecerbatgem.com/2016/09/23/rbc-capital-markets-reitera Sonnyusa 09/24/16 09:43:49 AM
#948   kevindenver are you still with Insy and if Sonnyusa 09/24/16 09:26:12 AM
#947   Nothing positive in the near future. Sonnyusa 09/23/16 05:39:26 PM
#946   Lots of upside Tho dmcc2087 09/22/16 10:42:06 AM
#945   Oops, there goes the INST CEO 236T568 09/21/16 01:36:50 PM
#944   In their defense, it's in their interest to StockPotential 09/15/16 06:43:27 PM
#943   INSY will get halted soon....still under SEC investigation... greens12 09/09/16 07:55:18 PM
#942   Glad to see INSY going down , I greens12 09/09/16 07:52:26 PM
#941   Uh oh Cbdpotential 08/30/16 09:28:59 AM
#940   Illinois' attorney general on Thursday sued Insys Therapeutics 236T568 08/25/16 01:39:07 PM
#939   Illinois attorney general sues Insys over fentanyl drug marketing 236T568 08/25/16 01:19:04 PM
#938   Yep! Glad to see this from last Thursday UserAlias1 08/24/16 10:59:24 AM
#937   Well done INSY! The Daily Waiter 08/24/16 10:20:21 AM
#936   Insys-Therapeutics (INSY) Announces Buprenorphine Sublingual-Spray Phase-3 Me UserAlias1 08/24/16 08:15:51 AM
#935   INSY Director sells $276,900 worth of INSY shares 236T568 08/13/16 01:59:18 PM
#934   What short and long term effect do you 2014shelby 08/11/16 10:06:18 PM
#933   Item 5.02 Departure of Directors or Certain Officers; 236T568 08/11/16 01:10:06 PM
#932   the writing is on the wall >>>>> we usgirls 08/03/16 11:22:39 AM
#931   There's a pulse! Cbdpotential 08/03/16 10:22:27 AM
#930   Biotech Movers: Insys Therapeutics and Cempra http://marketexclusive.com/biote venturecapp 07/05/16 02:24:58 PM
#929   http://www.fiercebiotech.com/biotech/insys-to-take-abbvie-fda-approval-for-oral- Cbdpotential 07/05/16 01:39:52 PM
#928   20 Cbdpotential 07/05/16 09:37:42 AM
#927   14 Cbdpotential 07/05/16 08:54:48 AM
#926   Syndros Approved for next phase @WolfofWeedST 07/05/16 07:33:48 AM
#925   Fda remakes after hours. If it's good and @WolfofWeedST 07/01/16 03:35:29 PM
#924   So will we find out during trading hours kabboki 07/01/16 07:16:12 AM
#923   Nasday up 75 points, IBB up 2%,and this ottoman 06/29/16 01:23:17 PM
#922   Sorry, 236T568. A documented fully on topic terry hallinan 06/28/16 06:00:30 PM
#921   Things just got worse for INSY: 236T568 06/28/16 12:27:20 PM
#919   short interest INSY 74.9% ottoman 06/28/16 09:13:40 AM
#918   This could be another reason, other than Brexit, 236T568 06/27/16 06:25:46 PM
#917   Just did some digging, I wouldn't recommend holding djmurdock 06/27/16 06:25:41 PM
#916   hope so, entered today at 12.44. added at ottoman 06/27/16 06:19:32 PM
#915   Over sold??? djmurdock 06/27/16 06:09:05 PM
#914   old news. terry hallinan 06/26/16 10:18:25 AM
#913   old news. kelleyy 06/25/16 12:13:44 AM
#912   Did you read this? Be careful dude, this djmurdock 06/24/16 12:41:37 PM
#911   Dear Wondering, terry hallinan 06/19/16 07:16:11 PM
#910   Lol dmcc2087 06/18/16 08:54:59 PM
#908   I believe we are going to run like dmcc2087 06/18/16 12:06:22 AM
#907   It's a multi million dollar company and I dmcc2087 06/18/16 12:05:52 AM
#906   This has been on my watch list for Mr_Doug 06/17/16 11:10:29 PM
#905   Any investors here? I'm in dmcc2087 06/15/16 01:28:20 PM
#904   Drug Maker’s Former Employees Accused of Shady Dealings 236T568 06/11/16 06:27:55 PM
#903   Fentanyl Claims Prince - What It Means To You 236T568 06/02/16 07:50:29 PM
#902   Prince died of accidental overdose of opioid fentanyl, 236T568 06/02/16 07:49:36 PM
#901   8- 12 near term would be nice. Positivevibes 03/28/16 01:57:02 AM
#900   Mini shortsqueeze to 24.00 is possible after the greens12 02/02/16 11:47:54 PM
#899   Great trade! After covering, you think a squeeze UserAlias1 02/02/16 11:44:40 AM
PostSubject